Cidara Entered into a License Agreement with Melinta to Commercialize Rezafungin for Candidemia and Invasive Candidiasis in the US
Shots:
- Cidara to receive a $460M incl. $30M up front, $60M in regulatory milestones, ~$370M in commercial milestones along with royalties on net sales of rezafungin in the US. Melinta gets an exclusive license to commercialize rezafungin in the US
- Cidara will be responsible for completing an ongoing P-III (ReSPECT) prophylaxis study, CMC & other activities for the approval of rezafungin in the US & also holds the rights to rezafungin in Japan while Mundipharma holds the commercial rights outside the US & Japan
- On July 2022, Cidara submitted rezafungin's NDA to the US FDA for candidemia & invasive candidiasis with an expected PDUFA date in Q1'23, if NDA is accepted for review following application validation
Ref: GlobalNewswire | Image: Cidara Therapeutics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
